Evidence map›Paper›PMID 31046781›Full record

ArticleJournal of experimental & clinical cancer research : CR2019

MicroRNA-139 inhibits hepatocellular carcinoma cell growth through down-regulating karyopherin alpha 2.

Ying Zan, Baofeng Wang, Liang Liang, Yujiao Deng, Tian Tian, Zhijun Dai, Lei Dong

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ying ZanDepartment of Oncology, the Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710004, China.
Baofeng WangDepartment of Oncology, the Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710004, China.
Liang LiangDepartment of Oncology, the Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710004, China.
Yujiao DengDepartment of Oncology, the Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710004, China.
Tian TianDepartment of Oncology, the Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710004, China.
Zhijun DaiDepartment of Oncology, the Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710004, China. dzj0911@126.com.
Lei DongDepartment of Gastroenterology, the Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710004, China. dong556@126.com.
Second Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

Central Leading Local Science and Technology Development Special Fund Project No.2016ZY-HM-01
6 · The paper itself

Abstract

backgroundMicroRNA-139-5p (miR-139) has been shown to play important roles in hepatocellular carcinoma (HCC) development. However, the exact mechanism of miR-139 in HCC remains largely unknown.

methodsWe investigated the function in human cell lines and patient tissue samples by experimental techniques in molecular biology including Co-IP assay, cell viability assay, quantitative real-time-PCR, et al. In addition, datasets were used to verify the results by database analysis. Statistical analysis was performed by using the GraphPad Prism 6 (GraphPad Software Inc., USA). A P value < 0.05 was defined as statistically significant.

resultsIn this study, we found that miR-139 was significantly down-regulated in HCC. MiR-139 level was negatively associated with the stage of HCC, and HCC patients with higher miR-139 level had longer overall survival (OS) than these having lower miR-139 expression. Overexpression of miR-139 led to reduced cell viability, elevated apoptosis, and decreased colony forming, migratory and invasive capacities in HCC cells, while down-regulation of miR-139 led to opposite phenotypes. MiR-139 also inhibited HCC growth in a xenograft mouse model. We identified karyopherin alpha 2 (KPNA2) as a direct target of miR-139. KPNA2 is up-regulated in HCC and higher KPNA2 level is associated with poor patient prognosis. Silencing of KPNA2 expression led to similar phenotypic changes as miR-139 overexpression. Restoration of KPNA2 attenuated the suppressive effects of miR-139 overexpression on cell viability, apoptosis, colony formation, migration and invasion. In addition, miR-139 overexpression and KPNA2 depletion led to decreased nucleus level of POU class 5 homeobox 1 (POU5F1) and c-myc, two well-known pro-oncogenes.

conclusionIn together, these data revealed the essential roles of the miR-139/KPNA2 axis in HCC.

Indexed as

alpha KaryopherinsApoptosisCarcinoma, HepatocellularCell MovementCell ProliferationEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHep G2 CellsHumansLiver NeoplasmsMaleMicroRNAsNeoplasm InvasivenessOctamer Transcription Factor-3Proto-Oncogene Proteins c-mycalpha KaryopherinsKPNA2 protein, humanMicroRNAsMIRN139 microRNA, humanMYC protein, humanOctamer Transcription Factor-3POU5F1 protein, humanProto-Oncogene Proteins c-mycColony formationEpithelial-to-mesenchymal transitionMigration and invasionSurvival

Identifiers

PMID31046781
PMCPMC6498602
OpenAlexW2947773036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.